Recruiting
PHASE2
INTERVENTIONAL
NCT07091734
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Participants will receive study drug (Tirzepatide) according to the dose titration plan described in the FDA-approved Prescribing Information (starting with 2.5 mg/wk and increasing the dose every 4 weeks by increments of 2.5 mg.
Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial.
Name:
Usual care medications
Type:
DRUG
Description:
Participant's will continue on participant's regular diabetic and hypertriglyceridemia medications that were used during the run-in period for 24 weeks. This will be either Phase 1 or Phase 2 based on randomization.
Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial.
Primary Outcomes
Measure:
Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks
TimeFrame:
Baseline, 24 weeks
Description:
Height and weight will be collected to calculate BMI.
Measure:
Change in Hemoglobin A1c from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks
TimeFrame:
Baseline, 24 weeks
Description:
The A1c is a blood test.
Trial Information
NCT ID
NCT07091734
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
University of Michigan
Last Updated
December 15, 2025